Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318421 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL25320538 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181293 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL25316108 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181392 | 0.98 | TBXAS1 (0.56) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181705 | 0.92 | — | — | |
| SCHEMBL28062565 | 0.89 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL503743 | 0.89 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL3431746 | 0.87 | TBXAS1 (0.66) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181657 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-116515023-A | Composition and cured product | 东京应化工业株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-116514161-A | Nanoparticle, nanoparticle dispersion liquid, and method for producing nanoparticle | 东京应化工业株式会社 | 2023-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | CD63, NIBAN2, ZRANB2 | TBXAS1 1738/4885TERT 1995/4885ALOX15 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.